Highlight
• LLDAS (Lupus Low Disease Activity State) is achievable in nearly half of patients with lupus nephritis at 12 months post-biopsy.
• Attainment of LLDAS independently predicts a lower risk of lupus nephritis relapse and better preservation of renal function.
• LLDAS and conventional renal response targets are complementary: achieving both provides the lowest risk for relapse.
• Findings are validated across two large tertiary hospital cohorts in Hong Kong, reinforcing generalizability.
Background
Lupus nephritis (LN) remains a major cause of morbidity and mortality in systemic lupus erythematosus (SLE), affecting up to 60% of SLE patients and contributing significantly to end-stage renal disease worldwide. Traditional management focuses on induction and maintenance immunosuppression, with treatment goals centered on achieving complete or partial renal response, typically defined by reductions in proteinuria and stabilization of serum creatinine. Despite advancements, relapse rates remain high, and optimal long-term targets remain debated. The lupus low disease activity state (LLDAS), a composite clinical measure encompassing global SLE activity, has shown utility in general SLE populations but has seldom been formally evaluated as a treatment goal in lupus nephritis.
Study Overview and Methodological Design
Cheung et al. (2025) conducted a prospective cohort analysis at two tertiary hospitals in Hong Kong, enrolling 143 patients with biopsy-proven active lupus nephritis (median SLE onset age: 28; 92% women). All patients received standard-of-care induction therapy with high-dose glucocorticoids and immunosuppressants, followed by maintenance immunosuppression. Clinical and laboratory evaluations were performed every 4 months, with assessment of both conventional renal response (complete/partial) and LLDAS at 12 months post-biopsy.
Renal relapse was rigorously defined: suspicion based on worsening proteinuria, urinary sediment, or rising creatinine, confirmed by repeat renal biopsy. The achievement rates of treatment targets, relapse risk, and preservation of renal function were compared between groups. A validation cohort of 102 patients (median SLE onset age: 30; 87% women) from a second hospital underwent the same protocol.
Key Findings
At 12 months, 40% achieved complete renal response, 10% partial response, and 49% attained LLDAS. Notably, LLDAS was as attainable as traditional renal response.
Risk stratification revealed that:
– Patients achieving neither renal response nor LLDAS faced the highest relapse risk.
– Achieving either target conferred intermediate risk.
– Achieving both yielded the lowest relapse risk.
Multivariate analysis confirmed independent associations:
– Achieving complete/partial renal response: hazard ratio (HR) 0.31 (P = 0.007)
– Achieving LLDAS: HR 0.38 (P = 0.029)
LLDAS also predicted better long-term renal function, with area under the curve (AUC) of 0.71 for renal preservation, comparable across both original and validation cohorts.
Mechanistic Insights and Pathophysiological Context
LLDAS is a composite measure that incorporates not only renal but also extra-renal SLE manifestations, serological activity, and glucocorticoid exposure. Achieving LLDAS likely reflects more comprehensive immunological control, which may reduce the risk of subclinical inflammation and subsequent renal injury—a plausible explanation for its predictive utility. The findings support the hypothesis that broader disease control, rather than renal parameters alone, underpins better long-term renal outcomes in LN.
Clinical Implications
The study provides compelling evidence that LLDAS is a feasible and meaningful treatment target in lupus nephritis. Integrating LLDAS attainment into routine clinical monitoring could improve risk stratification, facilitate tailored immunosuppression tapering, and inform patient counseling. Importantly, using LLDAS alongside conventional renal response targets may better identify patients at lowest risk for relapse and guide decisions on maintenance therapy duration.
For clinical practice, this suggests:
– Routine assessment of LLDAS at 12 months post-biopsy in LN patients.
– Consideration of both renal and systemic disease activity in therapeutic decision-making.
– Use of LLDAS as an endpoint in future LN clinical trials, potentially harmonizing research and practice metrics.
Limitations and Controversies
Although robust, the study has limitations. It is observational, and while validation across two cohorts strengthens findings, causality cannot be established. The cohort is predominantly Asian and female, potentially limiting generalizability to other ethnic groups. The definition of LLDAS, while standardized, may require adaptation in severe LN or in populations with different disease phenotypes. Furthermore, the optimal timing and frequency for LLDAS assessment beyond 12 months remains unclear. There are also no data on quality-of-life or patient-reported outcomes associated with LLDAS attainment in LN.
Expert Commentary or Guideline Positioning
Current lupus nephritis guidelines (e.g., ACR, EULAR/ERA-EDTA) focus on proteinuria and renal function as primary endpoints. The integration of LLDAS as a co-primary or secondary outcome is not yet routine. However, these results echo the growing trend toward holistic SLE management and may prompt guideline revisions. As Dr. Michelle Petri, a leading lupus nephritis expert, has commented in prior reviews, “comprehensive control of systemic activity—not just the kidney—remains an unmet goal in the field.”
Conclusion
LLDAS is an attainable, clinically meaningful target in lupus nephritis, independently predicting reduced relapse risk and preservation of renal function. These findings support the inclusion of LLDAS as a treatment goal and clinical trial endpoint in LN, marking a shift toward holistic disease management. Larger, multi-ethnic, and interventional studies are warranted to confirm these observations and clarify optimal implementation strategies.
References
1. Cheung CK, Yap DY, Lee KL, Li PH, Tang IY, Lau CS, Chan SC. Treating lupus nephritis patients to lupus low disease activity reduces renal relapse and preserves long-term kidney function. Arthritis Care Res (Hoboken). 2025 Jul 20. doi:10.1002/acr.25611 IF: 3.3 Q2 . Epub ahead of print. PMID: 40685846 IF: 3.3 Q2 .2. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745.3. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797-808.
